Year: 2021
BERGENBIO TO PRESENT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
April 28, 2021
Bergen, Norway, 28 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRTUAL IMMUNOLOGY 2021
April 26, 2021
Bergen, Norway, 26 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO ANNOUNCES UPDATE FROM INVESTIGATIONAL PHASE II TRIALS ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
April 19, 2021
· Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and ACCORD2_002·…
Read MoreBERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB ARM IN UK ACCORD COVID PLATFORM TRIAL
March 30, 2021
Bergen, Norway, 30 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO ASA: Minutes from the Annual General Meeting
March 19, 2021
Bergen, Norway, 19 March 2021 – Annual General Meeting in BerGenBio ASA (OSE:BGBIO) was virtually held on…
Read MoreBERGENBIO COMPLETES ENROLMENT INTO LATEST COHORT OF PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC
March 12, 2021
Bergen, Norway, 12 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read More
